ASCO Highlights

Geoffrey Ku, ASCO GI 2021 – the Addition of Durvalumab to Chemoradiation for Esophageal Adenocarcinoma

We were delighted to talk to Geoffrey Ku (Memorial Sloan Kettering Cancer Center, New York, US) about the addition of durvalumab to induction FOLFOX and PET-directed chemoradiation for esophageal adenocarcinoma (Clinical Trial Identifier: NCT02962063). The abstract ‘Durvalumab (D) and PET-directed chemoradiation (CRT) after induction FOLFOX for esophageal adenocarcinoma’ (ABSTRACT NUMBER: 226) was presented at the […]

Bladder Cancer

Thomas Powles, ASCO20: JAVELIN Bladder 100 Phase III Interim Analysis

It was a pleasure to speak to Thomas Powles about his plenery session on the phase III interim analysis of the JAVELIN Bladder 100 study on maintenance avelumab and best supportive care (BSC) versus BSC alone after platinum-based first-line chemotherapy in advanced urothelial carcinoma. Questions 1. What have we learned so far from clinical trials […]

Genitourinary Cancers

Axel Merseburger, ASCO20: Clinical Updates in Urothelial Carcinoma and Renal Cell Carcinoma

We are joined by touchONCOLOGY European Oncology & Haematology Editor-in-Chief Dr Axel S Merseburger to discuss his highlights from the JAVELIN Bladder 100 Trial (Clinicaltrials.gov identifier: NCT02603432) and the KEYNOTE-426 phase III trial in patients with clear cell renal cell carcinoma (ClinicalTrials.gov identifier: NCT02853331). Questions 1. What are the current unmet needs in the treatment […]

Breast Cancer

Priyanka Sharma, ASCO20: New Combination Therapy in the Treatment of Triple-Negative Breast Cancer

Priyanka Sharma, University of Kansas, joins us to discuss the data from the SWOG S1416 study (Clinicaltrials.gov identifier: NCT02595905) presented at the ASCO20 Virtual Scientific Programe on the combined use of PARP inhibitors and chemotherapy in the treatment of triple-negative breast cancer. Questions 1. What are the major unmet needs in the treatment of triple-negative […]

Breast Cancer

Anna van der Voort, ASCO20: Three-year Follow-up of the TRAIN-2 Phase III Trial

We were delighted to speak to Dr Anna van der Voort, The Netherlands Cancer Institute, to discuss her presentation at the ASCO20 Virtual Scientific Program on the long-term follow-up data of the randomised, multicentre, open-label phase III TRAIN-2 trial (ClinicalTrials.gov Identifier: NCT01996267). Questions 1. What are the major unmet needs in current neoadjuvant chemotherapy regimes […]

Multiple Myeloma

Shaji Kumar, ASCO20: Efficacy and Toxicity in the Randomised Phase III ENDURANCE Trial in Myeloma

We are joined by touchONCOLOGY’s Oncology & Hematology Review (US) Editor-in-Chief Shaji Kumar, Mayo Clinic, to discuss his plenary session at ASCO20 on the efficacy and toxicity in the randomized phase III ENDURANCE trial of the use of bortezomib, lenalidomide and dexamethasone for initial therapy of newly diagnosed multiple myeloma. Questions 1. What is the […]

Lung Cancer

Kazuhiko Nakagawa, ASCO 2019 – Phase III RELAY trial

At the ASCO 2019 annual meeting, trial investigator, Kazuhiko Nakagawa discusses RELAY: A multinational, double-blind, randomized Phase III study of erlotinib in combination with ramucirumab or placebo in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NCT02411448). Questions 1. What is the rationale for the use of ramucirumab […]

Paediatric Oncology

Cornelis van Tilburg, ASCO 2019 – Larotrectinib in paediatric TRK fusion cancer

At the ASCO 2019 annual meeting, Cornelis van Tilburg discusses findings from recent studies investigating the efficacy and safety of larotrectinib in paediatric TRK fusion cancer patients (NCT02637687 and NCT02576431) and what this means for the future. Questions 1.What percentage of paediatric tumours have tropomyosin receptor kinase (TRK) fusions and in what tumour types are […]

Renal Cancer

James Brugarolas, ASCO 2019 – Advances in sarcomatoid RCC

At the ASCO 2019 annual meeting, James Brugarolas discusses sarcomatoid renal cell carcinoma, the current challenges and the advances that are defining a new treatment paradigm. Questions 1. What is sarcomatoid renal cell carcinoma (RCC) and what is its prognosis? (0:04) 2. What are the major treatment challenges in sarcomatoid RCC? (0:54) 3. Why is […]

FILTER YOUR SEARCH

Speciality: